# MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Source: https://onco.cc/trials/nct03896568/  
OnCo record `nct03896568` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of DNX-2401 run by M.D. Anderson Cancer Center, now recruiting.

## Summary

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma is a phase 1 interventional study registered as NCT03896568 by M.D. Anderson Cancer Center, with 36 participants planned, started 2019-02-12. Conditions recorded: IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma and Recurrent Malignant Glioma. Interventions recorded: Oncolytic Adenovirus Ad5-DNX-2401 and Therapeutic Conventional Surgery.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03896568
- Phase: 1
- Setting: Phase I Clinical Trial of Allogeneic Bone Marrow Human Mesenchymal Stem Cells Loaded With A Tumor Selective Oncolytic Adenovirus, DNX-2401, Administered Via Intra-Arterial Injection in Patients With Recurrent High-Grade Glioma
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT03896568: https://clinicaltrials.gov/study/NCT03896568

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [DNX-2401](https://onco.cc/drugs/dnx-2401/)
- companies: [DNAtrix](https://onco.cc/companies/dnatrix/)

---
JSON: https://onco.cc/api/v1/entities/nct03896568.json